An Extended Cost-Effectiveness Analysis of Publicly Financed HPV Vaccination to Prevent Cervical Cancer in China

Authors: Carol Levin, Monisha Sharma, Zachary Olson, Stéphane Verguet, Ju-Fang Shi, Shao Ming Wang, You-Lin Qiao, Dean Jamison, Jane J. Kim

Citation:
Levin, C. , Sharma, M. , Olson, Z. , Verguet, S. , Shi, J. , et. al. . “An Extended Cost-Effectiveness Analysis of Publicly Financed HPV Vaccination to Prevent Cervical Cancer in China”. In: Disease Control Priorities (third edition): Volume 3, Cancer, edited by H. Gelband , P. Jha , R. Sankaranarayanan , S. Horton . Washington, DC: World Bank.
Levin, C. , Sharma, M. , Olson, Z. , Verguet, S. , Shi, J. , et. al. . “An Extended Cost-Effectiveness Analysis of Publicly Financed HPV Vaccination to Prevent Cervical Cancer in China”. In: Disease Control Priorities (third edition): Volume 3, Cancer, edited by H. Gelband , P. Jha , R. Sankaranarayanan , S. Horton . Washington, DC: World Bank.
Copy to Clipboard
Download Citation
Abstract:

The cost-effectiveness of offering publicly financed HPV vaccination in China to girls ages 9–15 years, which is anticipated to prevent 381,000 cervical cancer cases and 212,000 related deaths in the coming decades, is analyzed in this chapter. An extended cost-effectiveness analysis is developed to measure the impact of such a program in terms of health benefits, household expenditures savings, financial risk protection for households, and consequences across all strata of country population. The analysis included a simulation model, strategies of screening with cytology and visual inspection with acetic acid (VIA) at five-year intervals, cost data from two previous cancer studies in China, and sensitivity analysis. The HPV vaccine holds great promise for reducing the burden of cervical cancer, but the vaccine is not yet available in China.

 

 

AttachmentsSize
DCP3 Cancer_Ch 18.pdf
121.23 KB
Annex 18A_DCP3_ Cancer_Ch18.pdf
366.81 KB